Enzyme Inducers - Carbamazepine Flashcards
Dr. Aderemi
Carbamazepine is a _______ derivative used as a prophylactic in chronic epilepsy therapy.
Iminostilbene
It is also used to treat _________________ and ____________.
Trigeminal neuralgia and bipolar affective disorder
At standard dose, CBZ may cause convulsion and CNS toxicity.
True or False?
True
The therapeutic range for carbamazepine is _______.
4-12μg/mL
At ________, patients may experience concentration-related adverse effects.
> 8μg/mL
Mention 7 concentration-related adverse effects of CBZ.
i. Nausea
ii. Vomiting
iii. Lethargy
iv. Headache
v. Diplopia
vi. Blurred vision
vii. Ataxia
viii. Incoordination
Concentration-related toxicity of CBZ may manifest as ________
Osteoporosis
Blood dyscrasias, such as aplastic anaemia and agranulocytosis.
CBZ treatment is discontinued when WBC is ________ and ANC is _________.
WBC<2500/mm3
ANC<1000/mm3
ANC is Absolute Neutrophil Count
CBZ causes AED hypersensitivity syndrome and cross-reactivity with other aromatic anticonvulsants such as ___________, ___________, __________ and other drugs that cause AED hypersensitivity syndrome.
Oxcarbazepine
Phenobarbital
Phenytoin
There are injectable CBZ preparations.
True or False.
False.
There is no injectable CBZ
List the available oral dosage forms of CBZ.
- Immediate-release tablet (regular: 100mg, 200mg, 300mg and chewable: 100mg)
- Sustained-release tablet (100mg, 200mg and 400mg)
- Sustained-release capsules (100mg, 200mg and 300mg)
- Suspension 100mg/5ml
Answer with True or False:
i. CBZ is an auto-inducer
ii. Its adverse effects can be seen early in dosage titration, soon after an dosage increase.
i. True
ii. True
Absorption 0f CBZ is rapid and Tmax depends on ________.
The dosage form
Provide the values for the following CBZ pharmacokinetic parameters.
Bioavailability =
Vd =
Plasma Protein binding =
Free unbound drug =
Bioavailability = 75-85%
Vd = 0.8-2.0L/kg
Plasma Protein binding = 75-80%
Free unbound drug = 20-25%
In the plasma, CBZ binds to albumin and ________
α1-acid glycoprotein (AGP)
The active metabolic product of CBZ is _________ and the protein binding is ________
Carbamazepine-10,11-epoxide
50%
AGP is much higher in patients with stress, heart trauma, myocardial infarction and heart failure.
What is the effect of this on CBZ?
Increased CBZ binding to AGP resulting in lower free unbound drug (10-15%)
CBZ is extensively metabolised in the liver by ______
CYP3A4
CBZ is a hepatic enzyme inducer and auto-inducer. As a result, drug must be titrated upward starting with _______of the desired dose and increased by a similar amount every ______ until the total desired daily dose is achieved, allowing liver enzyme induction and CBZ clearance to increase slowly over a time period of _____.
- One-third to one-fourth
- 2-3 weeks
- 6-12 weeks
Highlight the effect of liver cirrhosis and acute hepatitis on CBZ pharmacokinetics and dosing.
i. Decreased metabolism
ii. Decreased clearance
iii. Decreased plasma binding
iv. Increased Vd (due to iii.)
v. Increased free unbound drug (due to iii.)
Highlight the effect of old age on CBZ pharmacokinetics and dosing.
Decreased clearance
Hence lower initial doses (100mg/day should be used)
Highlight the effect of pregnancy and lactation on CBZ pharmacokinetic and dosing.
There is decreased CBZ clearance in 3rd trimester
Thus dosage adjustment is required.
Breast milk conc is 60% of serum conc.
Renal failure does not warrant dosage adjustment of CBZ.
True or False?
True.
CBZ is a potent inducer of hepatic drug metabolizing enzyme systems and P-glycoprotein.
True or False?
True
Hepatic metabolic enzymes induced by CBZ include:
i. CYP 3A4
ii. CYP 2C9
iii. CYP 1A2
Induction of CYP3A4 results in the acceleration of metabolism of concurrently prescribed
anticonvulsants, such as ________.
i. Valproic acid
ii. Clonazepam
iii. Ethosuximide
iv. Lamotrigine
CBZ increases clearance and decreases steady-state concentrations of many other drugs including:
- Oral contraceptives
- CCBs
- TCAs
- Warfarin
- Theophylline
- Cyclosporine
- Tacrolimus
Mention 5 drugs that inhibit metabolic enzymes and cause CBZ toxicity.
- Cimetidine
- Macrolides
- Azole antifungals
- Diltiazem
- Fluoxetine
- Verapamil
- Indinavir
- Ritonavir
Mention 2 drugs that may increase CBZ clearance and reduce Css.
- Phenytoin
- Phenobarbital
How do you minimise CBZ interactions?
- Avoid polypharmacy
- Select drugs with lower potential for interaction
- Adjust dosage based on serum concentration monitoring